Indicated for Chronic Lymphocytic Leukemia

RITUXAN® (Rituximab) plus FC chemotherapy is indicated for the treatment of
patients with:

  • Previously untreated CD20-positive CLL
  • Previously treated CD20-positive CLL

Please see the full prescribing information, including BOXED WARNINGS and Medication Guide.

Chronic lymphocytic leukemia, or CLL, is a type of cancer. You may have just been told you have CLL. Or you may have been living with CLL for many years. Throughout your disease, you may or may not have symptoms. Whatever the case, watching your health can help you talk to your doctor about your CLL and be more involved in your care.

RITUXAN Support Center

(888) 455-2220

24 hours a day, 7 days a week

Call to speak with a live Nurse Educator who can:

  • Answer questions about CLL and RITUXAN
  • Offer materials to help you cope with CLL and
  • Connect you with helpful resources
 

RITUXAN Access Solutions

(888) 249-4918

Mon-Fri 6 am- 5 pm PST

RITUXAN Access Solutions helps resolve specific access and reimbursement issues for individual patients.

More Info

 

RITUXAN Co-Pay Card Program

 

The RITUXAN Co-Pay Card Program helps eligible patients with their monthly commercial insurance co-payments for RITUXAN.

 

More Info

 

This information does not take the place of talking with your doctor. Discuss with your doctor any questions you have about your medical condition or your treatment.

INDICATIONS and IMPORTANT SAFETY INFORMATION

RITUXAN® (Rituximab) is indicated in combination with fludarabine and cyclophosphamide (FC chemotherapy) for the treatment of patients with:

  • Previously untreated CD20-positive CLL
  • Previously treated CD20-positive CLL

People with serious infections should not receive RITUXAN.

IMPORTANT SAFETY INFORMATION

  • RITUXAN can cause serious side effects that can lead to death, including: infusion reactions, tumor lysis syndrome (TLS; kidney failure due to fast breakdown of cancer cells), severe skin and mouth reactions, and progressive multifocal leukoencephalopathy (PML; a rare, serious brain infection).
  • RITUXAN has also been associated with serious and life-threatening side effects, including: the return of active hepatitis B virus infection with sudden and serious liver problems including liver failure, and death, other serious infections that can lead to death, heart problems, kidney problems, and stomach and serious bowel problems including blockage and tears in the bowel that can sometimes lead to death.
  • The most common side effects of RITUXAN seen in clinical trials of patients with CLL were infusion reactions and low white blood cells, which can increase the risk of infections. Before starting treatment with RITUXAN it is important for you to talk to your doctor about your medical history.
  • Tell your doctor about any side effect that bothers you or that does not go away. These are not all of the possible side effects with RITUXAN. For more information, ask your doctor.

Please see full Prescribing Information, including Medication Guide.